New study lets MG patients rate their own symptoms on rystiggo
NCT ID NCT07570589
First seen May 07, 2026 · Last updated May 16, 2026 · Updated 2 times
Summary
This study watches 50 adults with generalized myasthenia gravis (gMG) who are taking the drug Rystiggo (rozanolixizumab). It does not test the drug itself, but instead uses a new patient questionnaire to track how symptoms like fatigue and muscle weakness change over 9 months. The goal is to understand the drug's real-world impact from the patient's point of view.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de NICE
Nice, Alpes-maritimes, 06000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.